NEW YORK (Genomeweb) - Epic Sciences announced today that it has completed a $52 million Series E financing.
The financing round was led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian. Existing investors also participated, including Altos Capital Partners, Genomic Health, Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management.
Epic said it plans to use the proceeds to advance the development of a portfolio of new predictive tests and decision support tools for precision medicine, based on its No Cell Left Behind technology. The firm's platform, which uses computer vision and machine learning algorithms to identify rare cancer cells in the blood, has thus far been employed for just one test — its prostate cancer AR-V7 assay, which is now marketed commercially in partnership with Genomic Health.
According to Epic, future tests based on the platform could track how populations of cancer and immune cells change under the selective pressure of different drugs, in order to predict which singular or combination therapies may be most effective for patients.
Epic said it also plans to take its platform through "appropriate regulatory approvals."